IGFBP2 and neoplasm: Tumor samples from high-risk group A showed a higher mean overall IHC score for Anti-MSX1, Anti-CD271, Anti-ERRFI1, Anti-PTPRF, Anti-TNFRSF21, Anti-TNFRSF12a, and Anti-IGFBP2, but without significance (Figure S2).